Baseline Patient characteristics
| Characteristics | Choice (n=24) | Toxicity (n=28) | Statistics |
| Median age | 67 years | 63 years | P=0.311 (two-sided t-test) |
| Male gender | 17 (71%) | 17 (61%) | P=0.444 (Pearson χ2) |
| ECOG PS 0–1 | 24 (100%) | 27 (96%) | - |
| LDH elevated | 7 (29%) | 8 (29%) | P=0.971 (Pearson χ2) |
| Primary tumor type | P=0.468 (Pearson χ2) | ||
| Cutaneous | 12 (50%) | 19 (68%) | |
| Acral | 1 (4%) | 0 | |
| Mucosal | 2 (8%) | 2 (7%) | |
| Unknown | 9 (38%) | 7 (25%) | |
| Disease stage at tx | P=0.115 (Pearson χ2) | ||
| III–IV M1b | 11 (46%) | 7 (25%) | |
| IV M1c/M1d | 13 (54%) | 21 (75%) | |
| BRAF mut (%) | 4 (17%)* | 12 (41%)† | P=0.064 (Pearson χ2) |
| Brain mets (%) | 10 (42%) | 7 (25%) | P=0.202 (Pearson χ2) |
| Prior systemic tx | 8 (33%) | 7 (25%) | P=0.508 (Pearson χ2) |
| Ipilimumab | 7 (29%) | 2 (7%) | P=0.036 (Pearson χ2) |
| BRAFi/MEKi | 1 (4%) | 4 (14%) | P=0.217 (Pearson χ2) |
| Therapy received | P=0.202 (Pearson χ2) | ||
| Anti-PD1/Anti-CTLA4 | 14 (58%) | 21 (75%) | |
| Anti-PD-1 | 10 (42%) | 7 (25%) |
*N=3 (13%) unknown BRAF status.
†N=5 (18%) unknown BRAF status.
CTLA4, cytotoxic T-lymphocyte-associated protein 4; LDH, lactate dehydrogenase; PD-1, programmed cell death protein 1; PS, performance status.